We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Adds Plasma Fibrinogen as Biomarker in COPD Trials
The item has been added to your shopping cart.
FDA Adds Plasma Fibrinogen as Biomarker in COPD Trials
The FDA is adding plasma fibrinogen as a prognostic biomarker for patient selection in clinical trials involving chronic obstructive pulmonary disease and a high risk of death.